Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220249595COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME
US 11.08.2022
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No 17472574 Applicant BioIncept, LLC. Inventor Eytan R. Barnea

Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide.

2.WO/2022/167798MOLECULE
WO 11.08.2022
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/GB2022/050280 Applicant AUTOLUS LIMITED Inventor MCKENZIE, Callum
The present invention provides a molecule which comprises a Fas-binding domain linked to an intracellular retention signal. When expressed in a cell, the molecule inhibits Fas expression at the cell surface and therefore Fas:FasL-mediated apoptosis.
3.WO/2022/170063IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING SAME
WO 11.08.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2022/015271 Applicant SALUBRIS BIOTHERAPEUTICS, INC. Inventor LI, John
The disclosure provides recombinant fusion proteins comprising an antigen binding domain specific for CTLA-4, an IL-15Ra sushi domain and IL-15. The disclosure further provides methods of using these recombinant fusion proteins in the treatment of cancer.
4.WO/2022/165609RECOMBINANT PLANT-DERIVED ANTIBODIES AND FC VARIANTS AND RELATED METHODS
WO 11.08.2022
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
Appl.No PCT/CA2022/050177 Applicant HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD Inventor MENASSA, Rima
The present application describes polypeptides comprising a variant Fc chain that exhibits enhanced accumulation in an organism and methods of producing the same. A method of enhancing accumulation of a protein is also described. The present application also describes polypeptides which specifically bind to intimin on an Escherichia coli cell, including antibodies and antigen-binding fragments thereof, and methods of producing the same. Also described is a method of preventing or reducing colonization of E. coli in the gastrointestinal tract of a mammal. A method of detecting the presence of E. coli in a sample is also described.
5.WO/2022/169269ANTI-CTLA-4 ANTIBODY AND USE THEREOF
WO 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/KR2022/001708 Applicant EUTILEX CO.,LTD. Inventor KWON, Byoung Se
The present invention relates to an anti-CTLA-4 antibody and, more specifically, to an anti-CTLA-4 antibody and a multi-specific antibody designed on the basis of the anti-CTLA-4 antibody. It has been identified that an anti-CTLA-4 antibody according to the present invention exhibits excellent binding to CTLA-4 and remarkably reduces tumor size in animal models. In addition, the multi-specific antibody designed on the basis of the anti-CTLA-4 antibody also exhibits excellent binding to antigen 4-1BB, and thus can more effectively inhibit tumors. Therefore, the anti-CTLA-4 antibody and the multi-specific antibody designed on the basis of the anti-CTLA-4 antibody, of the present invention, can be effectively used in the prevention or treatment of tumors or cancer and inflammatory diseases of interest.
6.WO/2022/169344NEWCASTLE DISEASE VIRUS WITH IMPROVED HEAT RESISTANCE, AND NEWCASTLE DISEASE VIRUS VACCINE COMPRISING SAME
WO 11.08.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/KR2022/001899 Applicant BIOPOA, INC. Inventor CHO, Sun Hee
The present specification provides: a Newcastle disease virus with improved heat resistance; a Newcastle disease vaccine comprising the virus; a polypeptide comprising an L protein in the virus; a polynucleotide encoding same; and a recombinant vector comprising the polynucleotide.
7.20220251191THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS
US 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17527982 Applicant Arch Oncology, Inc. Inventor James BLINN

Provided are compositions and methods for treating cancer by administering antiCD47 mAbs and anti-CD47 fusion proteins with distinct functional profiles or chimeric antigen receptor (CAR)-bearing immune effector cells in combination with analogs of interleukin proteins.

8.WO/2022/165918UNIVERSAL ANTI-CORONAVIRUS CONSERVATIVE EPITOPE IGY AND BROAD-SPECTRUM ANTI-NOVEL CORONAVIRUS IGY AND COMPOSITE ANTIBODY
WO 11.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/080581 Applicant SHENZHEN JASON INTELLIGENT BIOENGINEERING LTD. Inventor PAAU, Shing
Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention is a method for preparing the universal anti-coronavirus conservative epitope IgY and the broad-spectrum anti-variation novel coronavirus IgY antibody and an anti-mutation novel coronavirus IgY antibody and the combined antibody. Furthermore, the IgY and the composite IgY and the combined antibody can bind to a coronavirus universal conservative epitope and an antigen epitope with strong conservation, to achieve a broad-spectrum neutralizing virus effect, and the problems of coronavirus and novel coronavirus being prone to variation and immune escape and treating an asymptomatic patient are solved. Further provided in the present invention are a central air conditioner atomizing disinfectant and outer packaging disinfectant and an aerosol inhalation, spray, oral spray, nasal spray, nasal drops, eye drops, air disinfectant, hand sanitizer, powder, tablet, mouth lozenge, oral liquid and capsule made from the IgY and the composite IgY, which are used in drugs, disinfection products, health-care products and medical devices for preventing and treating coronavirus and novel coronavirus infections.
9.WO/2022/170193T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM3) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
WO 11.08.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2022/015496 Applicant INTELLIA THERAPEUTICS, INC. Inventor COOK, Danielle Ryan
Compositions and methods for editing, e.g., altering a DNA sequence, within a TIM3 gene are provided. Compositions and methods for immunotherapy are provided.
10.20220249644Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens
US 11.08.2022
Int.Class A61K 39/108
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
108Escherichia; Klebsiella
Appl.No 17271127 Applicant VESTLANDETS INNOVASJONSSELSKAP AS (VIS) Inventor Pål Puntervoll

The present invention relates to mutants of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant has two mutations wherein the first mutation is selected from L9K, L9N and L9T and the second mutation is A14T.